The Role of Small Molecule NMR in Medicinal Chemistry

In this on-demand webinar, Kathleen Farley, Senior Principal Scientist, R&D, Pfizer Inc, describes how nuclear magnetic resonance (NMR) spectroscopy is integrated into the Pfizer drug discovery pipeline and how the technique is used.

Webinar Overview

Since its early days, nuclear magnetic resonance (NMR) has played an important role in the pharmaceutical industry. NMR is traditionally used by medicinal chemists for structure elucidation of both synthesized molecules and active compounds isolated from natural sources. However, it can also be a valuable tool for reaction monitoring, the characterization of solution conformations, the investigation of metabolites, hit-to-lead optimization and quantitation.

In this on-demand webinar, Kathleen Farley, Senior Principal Scientist, R&D, Pfizer Inc, describes how NMR spectroscopy is integrated into the Pfizer drug discovery pipeline and how the technique is used in a walk-up environment by medicinal chemists and NMR scientists to solve challenging drug discovery problems.

Additionally, Anna Codina, Director Pharmaceutical Business Unit, Bruker BioSpin, finishes the webinar by presenting new additions to the NMR instrumentation family that make the technique available to a wider audience, overcoming some of the current cost concerns. This expansion includes both affordable high-resolution and benchtop instrumentation.

Speakers

Kathleen Farley
Senior Principal Scientist, R&D Pfizer Inc

Kathleen Farley is a Senior Principal Scientist in the R&D division at Pfizer Inc with over 30 years of experience in the pharmaceutical industry providing NMR support for Medicinal Chemistry research. She has taught the American Chemical Society (ACS) NMR course, “1D and 2D NMR Spectroscopy: Structure Determination of Small Molecule Organic Compounds” with Greg Walker for the last 10 years. Kathleen also has over 40 publications including a book chapter and two patents. Her current research includes the structural characterisation of small molecules and peptides using residual dipolar couplings.

Dr. Anna Codina

Director Pharmaceutical Business Unit, Bruker BioSpin

Anna has a degree in Chemistry and a PhD in Protein NMR from the University of Barcelona, Spain. During this time she did several industrial placements at pharmaceutical industries (Pharmhispania, Spain, and Genentech, SF, USA) and she worked for the NMR service of the University. She then moved to Cambridge, UK, to do a post-doc in protein NMR at the MRC Laboratory of Molecular Biology.

After her post-doc she worked in the Analytical R&D department of Pfizer, UK, for 8 years, becoming proficient in low level impurity structure elucidation, reaction monitoring, qNMR and the preparation of regulatory documentation.

She joined Bruker in 2011 as Material Characterisation Laboratory Manager. Since then her role has evolved. She started looking after the pharmaceutical market in 2015 as Product Portfolio Manager. Anna and team launched several products: InsightMR, InsightXpress and InsighCell for process understanding and monitoring; Fragment Based Screening analysis tools, PotencyMR for potency determination of drugs by qNMR; the minispec Form Check for solid form quantification and NMR Instrument Qualification packages to facilitate compliance. She is now director of the pharmaceutical business Unit at Bruker BioSpin.